Wolwo Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 345 million yuan, an increase of 26.67%Zhitong·Oct 23, 2025 at 06:41 AM300357+0.13%
A-share innovative drug concept stocks fluctuated and rose, Wolwo Pharma increased by over 10%, Chemexpress rose by over 9%, Fushine, CSBIO, and Medicilon followed suitZhitong·Oct 19, 2025 at 09:42 PM300357+0.13%300255+3.53%
Wolwo Pharma obtained the summary report of Phase I clinical trial for Aspergillus flavus puncture solutionZhitong·Sep 25, 2025 at 03:33 AM300357+0.13%
Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launchZhitong·Jul 22, 2025 at 04:42 AM300357+0.13%
Zhongtai Securities: Maintain Wolwo Pharma "Buy" rating, steady revenue growth, core products continue to expandZhitong·Jun 5, 2025 at 04:33 AM300357+0.13%
At the end of the first quarter, the social security fund held multiple innovative drug concept stocksZhitong·May 30, 2025 at 01:39 AM688266+4.00%300357+0.13%
Wolwo Pharma has obtained clinical trial approval for the dermatitis diagnostic patch 02Zhitong·May 19, 2025 at 05:08 AM300357+0.13%
Wolwo Pharma released its first-quarter performance, with a net profit attributable to the parent company of 74.3421 million yuan, a decrease of 3.71%Zhitong·Apr 18, 2025 at 07:11 AM300357+0.13%
Wolwo Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 318 million yuan, an increase of 2.46%Zhitong·Apr 18, 2025 at 07:07 AM300357+0.13%
Wolwo Pharma: The first subject has been enrolled in the Phase I clinical trial of the house dust mite membrane agentZhitong·Mar 27, 2025 at 03:32 AM300357+0.13%
Wolwo Pharma: Application for clinical trial of dermatitis diagnostic patch 02 has been acceptedZhitong·Mar 4, 2025 at 03:44 AM300357+0.13%
Wolwo Pharma 2024 Q1-Q3 dividend distribution: 1 yuan for every 10 shares, with the record date on January 9Zhitong·Jan 2, 2025 at 05:56 AM300357+0.13%
Wolwo Pharma: Approval obtained for the listing license application of 3 types of point injection productsZhitong·Dec 22, 2024 at 09:51 PM300357+0.13%
